
Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc. (CRDL.TO) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · CRDL.TO · as of Jun 8, 2026
Key Statistics
Explore Cardiol Therapeutics Inc. Data
crdl.to stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 3 · Buy rate: 100.0%
Competitors & Peers
crdl.to competitorsStock Performance
Full HistoryAbout Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc. a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease …
what is cardiol therapeutics inc. · crdl.to stock overview · cardiol therapeutics inc. company profile · who is cardiol therapeutics inc. ceo · crdl.to TSX · cardiol therapeutics inc. headquarters · cardiol therapeutics inc. business segments
About Stock Overview & Key Data
Cardiol Therapeutics Inc. (CRDL.TO) is a Healthcare company in the Drug Manufacturers - Specialty & Generic industry, listed on TSX since Dec 20, 2018. As of the latest trading session, CRDL.TO stock price is $1.55, with a market capitalization of $173.4M. The stock has returned -20.00% over the past 12 months and +19.08% year-to-date.
According to 3 Wall Street analysts, the consensus rating for Cardiol Therapeutics Inc. stock is Buy, with an average 12-month price target of $—. In fiscal year 2025, Cardiol Therapeutics Inc. reported revenue of — and net income of -$33.8M. For detailed data — including Cardiol Therapeutics Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Cardiol Therapeutics Inc. (CRDL.TO) stock price is $1.55. The stock is traded on TSX under the ticker symbol CRDL.TO. The 52-week range is $1.23 – $2.33.